Pinned
Faculty positions available for #myeloma clinician scientists. Join our @MDAndersonnews #Myeloma Team!
mdanderson.org/about-md-ander…
Please RT!
Robert Z. Orlowski
42.6K posts
Robert Z. Orlowski
@Myeloma_Doc
Deputy Chair of Lymphoma/Myeloma, Vice Chair MM Research @ MD Anderson; Translational researcher who hates myeloma. Tweets are my own. Retweets ≠ endorsements.
- Inequities in care are a reality for many with multiple #myeloma, a rare blood cancer. I’m teaming up with @JanssenUS to discuss driving #HealthEquity dialogue online with @MYELOMAhope, @Bethfaiman, and @KashyappatelMd: bit.ly/3ug8xnQ #HealtheVoicesHCP #RareDisease
- Riding out Hurricane Laura at MD Anderson to make sure our inpatients on the #Myeloma Service have uninterrupted care. Everyone please stay safe!
- Thanks for the kind words. Always thankful for the opportunity to work with wonderful #myeloma colleagues like you in the field.Congrats to @Myeloma_Doc @MDAndersonNews who was honored as a Giants of Cancer Care inductee yesterday in Chicago for his outstanding contributions to myeloma. Dr. Orlowski pioneered therapy with proteasome inhibitors for myeloma. @OncLive @SWOG cc: @SagarLonialMD #ASCO22
- #Myeloma Paper of the Day: Cool paper from @RahulBanerjeeMD showing analysis of S0777 and S1211 @SWOG trial data that lowering the dose of dex during induction therapy did not have an impact on long-term outcomes like PFS & OS: pubmed.ncbi.nlm.nih.gov/39321347/. #mmsm
- #Myeloma Paper of the Day: Comparison of standard-of-care Ide-cel and Cilta-cel in relapsed/refractory myeloma finds Cilta associated w/ higher likelihood of grade ≥3 CRS, SPMs, and delayed neurotox, but better treatment responses, PFS, and OS: pubmed.ncbi.nlm.nih.gov/39965175/. #mmsm
- #Myeloma Paper of the Day: Eagerly awaited new high-risk IMWG definition: 1. del 17p w/ >20% clonal frac &/or TP53 mut; 2. t(4;14), t(14;16), t(14;20) w/ 1q+ &/or del 1p32; 3. monoallelic del 1p32 w/ 1q+ or biallelic del 1p32; 4. β2 ≥5.5 & nl SCr: pubmed.ncbi.nlm.nih.gov/40489728/. #mmsm
- #Myeloma Paper of the Day: Analysis of Canadian Myeloma Research Group Database finds tandem autologous transplantation (vs. 1 ASCT) does not benefit high-risk myeloma patients (overall & in subgroups) in the maintenance era on either PFS or OS: pubmed.ncbi.nlm.nih.gov/38971462/. #mmsm
- #Myeloma Paper of the Day: D-KRd induction -> ASCT -> D-KRd consolidation -> second ASCT -> D-R maintenance for 2 years in high risk NDMM shows ORR of 100%, MRD negativity rate (by NGS @ 10(-6)) 94%, 30-month PFS & OS of 80% and 91%, respectively: pubmed.ncbi.nlm.nih.gov/38394666/.
- #Myeloma Paper of the Day: Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory myeloma achieve higher response rates (100% in 52 pts) vs. other options & increase clonality in the CD4+ and CD8+ T cell post_CAR T: pubmed.ncbi.nlm.nih.gov/39441177/. #mmsm
- #Myeloma Paper of the Day: Global study of 61,725 patients with newly diagnosed myeloma undergoing upfront AHCT from 9 national/international registries shows median OS 90.2 months & PFS 36.5 months with non-relapse mortality of 1%-3%: pubmed.ncbi.nlm.nih.gov/39158218/. #mmsm
- #Myeloma Paper of the Day: Long-term follow-up of Phase III CASSIOPEIA trial confirms Dara maintenance is superior to observation (HR 0.49; p<0.0001), and now shows that D-VTd + Dara maintenance is better than D-VTd w/o maintenance (HR 0.76; p=0.048): pubmed.ncbi.nlm.nih.gov/38889735/.
- #Myeloma Paper of the Day: Retrospective study finds that, among BCMA-directed therapies, CAR T-cells & T-cell engagers yield better outcomes vs. ADCs, but their efficacy is most impacted by prior BCMA-targeted therapy among the three classes of agents: pubmed.ncbi.nlm.nih.gov/39043638/.
